banner

AltiGen Records Lower Revenue in Q4, Trims Losses for Full Year

AltiGen Communications (ATGN) iFusion Phone

AltiGen Communications, Inc. (OTCQX: ATGN) reported steeper losses Wednesday from the fourth quarter and fiscal years ended September 30, 2012, as the company booked a one-time, non-cash charge for excess inventory.

Revenue for the fourth quarter fell 18.6 percent to $3.5 million, compared to $4.3 million in the year prior quarter.  Net loss from operations totaled $1.6 million, or 9 cents per share, versus a net loss of $861,000, or 5 cents per share in the fourth quarter of 2011.  According to the San Jose, California-based company, the increase in net loss for 2012 was primarily the result of a one-time non-cash charge for excess inventory of approximately $1.1 million.  The extra inventory also hamstringed gross margin during the quarter, which slid from 64.2 percent in Q4 2011 to 35.9% in the latest quarter.

“Our fiscal fourth quarter revenues reflect the continued softness in the overall premise PBX business. While we do not anticipate significant improvements in this business in the foreseeable future we do expect to see growth from our new MaxCloud hosted PBX business, which we plan to launch in calendar Q1,” said Jeremiah Fleming, president and chief executive at AltiGen.



The AltiGen chief noted a “significant” slowdown in sales of their iFusion SmartStations as a result of the new iPhone 5 changing to its new Lightning connector.  Apple’s (NASDAQ: AAPL) latest smartphone changed from the 30-pin connector used on previous models.  AltiGen is making the required changes to iFusion bases, according to Wednesday’s statement.

“This slowdown in unit sales has required us to make an allowance for excess inventory, for which the $1.1 non-cash charge was recorded in the quarter,” said Fleming.

AltiGen, a provider of integrated Microsoft-based Unified Communications solutions, trimmed operating expenses by a healthy 21.6 percent to $2.9 million during the fourth quarter.

For the twelve months ended September 30, 2012, revenue demurred by 4.5 percent to $16.9 million, compared to $17.7 million for fiscal 2011.  For the latest year, net loss tightened to $1.8 million, or 11 cents per share, from a net loss of $2.7 million, or 16 cents per share for fiscal 2011.

Gross margin was 60.1% for the twelve-month period of fiscal 2012, compared to 65.9% in the comparable period last year, as margins suffered from inventory reserves.

Operating expenses were $11.9 million for fiscal year 2012, a decrease of 17.4% from $14.4 million for fiscal 2011.

As of September 30, 2012, total cash and cash equivalents was $4.2 million and working capital was $1.3 million, compared to total cash and cash equivalents of $4.3 million and working capital of $2.1 million as of September 30, 2011.

Shares of AltiGen started the year at 30 cents each and closed Wednesday’s trading session on a 100-share trade at 27 cents.  Shares rose as high at 63 cents in February and sank as low as 16 cents in August.

AltiGen Communications (ATGN) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article, but owns shares of AltiGen Communications. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial(0)

Blue Calypso Inc. (OTCBB: BCYP), an innovator in digital social advertising, mobile content syndication, and analytics, recently announced a Markman hearing set for August 27, 2013 in its patent infringement case against LivingSocial. Findings from this hearing may encourage settlements or provide insight into the likelihood of a particular outcome. With the success seen by

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen(0)

One might think that celebrity endorsements would be fantastic for the share price of a small or microcap company. After all, famous and successful athletes or movie stars have a stack of cash to invest and the connections to help accelerate business developments. Oddly, though, it doesn’t seem to have a great deal of impact.

Sunvalley Solar Shares Rise from Bottom on Solar Installation Contract

Sunvalley Solar Shares Rise from Bottom on Solar Installation Contract(0)

Shares of Sunvalley Solar, Inc. (OTCBB: SSOL) are rising in trading Monday morning after the solar power technology company disclosed a new contract to 87.5-kilowatt solar system installation contract from Corporate Logistics in City of Industry, California. The contract is for a system capable of generating 131,146 kilowatt hours of electrical power each year, utilizing

Men’s Health Features Naked Brand Group Line of Underwear

Men’s Health Features Naked Brand Group Line of Underwear(0)

Naked Brand Group, Inc. (OTCQB: NAKD) said Friday that its Naked Boxer Brief has been selected by Men’s Health for its online guide, “Affordable Spring Style Guide 100 under $100.”  The guide was published on MensHealth.com on March 20.  This is the second time the company has been featured in the men’s mag in as

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials(0)

Sunshine Biopharma Inc. (OTCQB: SBFM) reported on Thursday that it is in negotiations with Contract Manufacturing Organizations, or CMOs, as the next progression towards the anticipated clinical trials of its flagship cancer drug, Adva-27a, against multi-drug resistant forms of breast cancer. The trials are scheduled to be hosted by the leading cancer center Jewish General

read more
banner


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.